RxDoctor Payments DataLook up a doctor →

Ira Horowitz, MD

Critical Care Medicine · Cherry Hill, NJNPI 1780682278

Payments from drug & device makers

$7,443in general payments, 2019–2025

Across 451 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Inari Medical, Inc.$366
  • Mylan Specialty L.p.$343
  • Regeneron Healthcare Solutions, Inc.$338
  • Philips North America LLC$334
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,443 in reported general payments places this provider in the 85th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$228,582
Medicare patients
849
Services billed
2,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter305$339,989
Breo ElliptaFluticasone/Vilanterol147$105,500
XolairOmalizumab15$96,420
Fasenra PenBenralizumab14$82,678
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$42,615
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$34,984
Arnuity ElliptaFluticasone Furoate57$28,267
Spiriva RespimatTiotropium Bromide21$24,753
EliquisApixaban24$19,043
Albuterol Sulfate HfaAlbuterol Sulfate397$16,865
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$9,502
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$9,496
SymbicortBudesonide/Formoterol Fumarate26$8,992
Incruse ElliptaUmeclidinium Bromide17$8,302
Varenicline Tartrate34$6,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$1,747$517,041572 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,779$51,60764 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$259$34,24939 claims
PfizerEliquis$55$19,04324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 critical care medicine providers in New Jersey.

Other critical care medicine in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →